Skip to main content
SpringerLink
Log in

Neonatal Immune Hemolytic Anemia

  • Chapter
  • First Online:
Benign Hematologic Disorders in Children

  • 693 Accesses

Abstract

Of all neonatal anemias, immune hemolytic anemia is a significant cause of morbidity and even mortality when appropriate management is not available. With the creation of guidelines for evaluation and management of hemolytic disease of the fetus and newborn (HDFN), the devastating effects of neonatal immune hemolytic anemia have significantly declined, especially in the developed world. Understanding of the pathophysiology and natural history of HDFN are key elements for the proper evaluation and management of infants affected by this condition.

This chapter presents basic pathophysiology of HDFN, current evidence-based treatment, and new directions for clinical guidance on the management of HDFN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Reid ME, Lomas-Francis C. The blood group antigen facts book. 2nd ed. Amsterdam: Elsevier Academic Press; 2004.

    Google Scholar 

  2. Zipursky A, Israels LG. The pathogenesis and prevention of Rh immunization. Can Med Assoc J. 1967;97:1245–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Barrett J. The essay. Bowman, John. The management of hemolytic disease in the fetus and newborn. Semin Perinatol. 1997;21(1):39.

    Article  Google Scholar 

  4. Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, Jones J, Allard S. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014;24:8–20. https://doi.org/10.1111/tme.12091.

    Article  CAS  PubMed  Google Scholar 

  5. Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA. 1991;265:3270–4.

    Article  CAS  PubMed  Google Scholar 

  6. Yazer MH, Brunker PA, Bakdash S, Tobian AA, Triulzi DJ, Earnest V, Harris S, Delaney M. Low incidence of D alloimmunization among patients with a serologic weak D phenotype after D+ transfusion. Transfusion. 2016;56:2502–9. https://doi.org/10.1111/trf.13725.

    Article  CAS  PubMed  Google Scholar 

  7. Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen facts book. Boston: Elsevier/Academic Press; 2012.

    Google Scholar 

  8. Simmons DP, Savage WJ. Hemolysis from ABO incompatibility. Hematol Oncol Clin North Am. 2015;29(3):429–43. https://doi.org/10.1016/j.hoc.2015.01.003. Epub 2015 Mar 10

    Article  PubMed  Google Scholar 

  9. Roberts IA. The changing face of haemolytic disease of the newborn. Early Hum Dev. 2008;84:515–23.

    Article  PubMed  Google Scholar 

  10. Eder AF. Update on HDFN: new information on long-standing controversies. Immunohematology. 2006;22:188–95.

    CAS  PubMed  Google Scholar 

  11. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015;2015:146–51.

    Article  PubMed  Google Scholar 

  12. Moise KJ Jr. Non–anti-D antibodies in red-cell alloimmunization. Eur J Obstet Gynecol Reprod Biol. 2000;92:75–81.

    Article  CAS  PubMed  Google Scholar 

  13. Public Health Service, Centers for Disease Control and Prevention, Congenital malformation surveillance. Teratology. 1993;48:545–709.

    Article  Google Scholar 

  14. Daniels G, Hadley A, Green CA. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion. 2003;43(1):115–6. PMID: 12519439. https://doi.org/10.1046/j.1537-2995.2003.00327.x.

    Article  PubMed  Google Scholar 

  15. Santhanakrishnan M, Tormey CA, Natarajan P, Liu J, Hendrickson JE. Clinically significant anti-KEL RBC alloantibodies are transferred by breast milk in a murine model. Vox Sang. 2016; https://doi.org/10.1111/vox.12387.

  16. Committee on Practice Bulletins-Obstetrics. ACOG practice Bulletin No. 192: management of alloimmunization during pregnancy. Obstet Gynecol. 2018;131(3):e82–90. https://doi.org/10.1097/AOG.0000000000002528.

    Article  Google Scholar 

  17. Lanzkowsky P. Anemia during the neonatal period. In: Lanzkowsky’s manual of pediatric hematology and oncology. https://doi.org/10.1016/B978-0-12-801368-7.00005-3.

  18. Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion. 2007;47:2126.

    Article  CAS  PubMed  Google Scholar 

  19. Finning KM, Martin PG, Soothill PW, Avent ND. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion. 2002;42:1079.

    Article  CAS  PubMed  Google Scholar 

  20. Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. Transfus Med Rev. 2016;30:159–64.

    Article  PubMed  Google Scholar 

  21. Johnstone-Ayliffe C, Prior T, Ong C, et al. Early procedure-related complications of fetal blood sampling and intrauterine transfusion for fetal anemia. Acta Obstet Gynecol Scand. 2012;91(4):458–62.

    Article  PubMed  Google Scholar 

  22. Ruma MS, Moise KJ Jr, Kim E, Murtha AP, Prutsman WJ, Hassan SS, et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. Am J Obstet Gynecol. 2007;196:138 [e1-6].

    Article  Google Scholar 

  23. Committee on Practice Bulletins-Obstetrics. ACOG practice Bulletin No. 181: prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57–70. https://doi.org/10.1097/AOG.0000000000002232.

    Article  Google Scholar 

  24. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.

    Article  Google Scholar 

  25. Bhutani VKJohnson LSivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999;103(1):6–14.

    Article  Google Scholar 

  26. Steiner L, Bizzarro M, Ehrenkranz R, Gallagher P. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007;120:27. https://doi.org/10.1542/peds.2006-2910.

    Article  PubMed  Google Scholar 

  27. Chitty HE, Ziegler N, Savoia H, et al. Neonatal exchange transfusions in the 21st century: a single hospital study. J Paediatr Child Health. 2013;49:825–32.

    Article  PubMed  Google Scholar 

  28. Steiner LA, Bizzarro MJ, Ehrenkranz RA, et al. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007;120:27–32.

    Article  PubMed  Google Scholar 

  29. Zwiers C, Scheffer-Rath MEA, Lopriore E, de Haas M, Liley HG. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev. 2018;(3):Art. No.: CD003313. https://doi.org/10.1002/14651858.CD003313.pub2.

  30. McDonald SJ, Middleton P, Dowswell T, Morris PS. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev. 2013;7:CD004074.

    Google Scholar 

  31. Rabe H, Reynolds G, Diaz-Rossello J. A systematic review and meta-analysis of a brief delay in clamping the umbilical cord of preterm infants. Neonatology. 2008;93(2):138–44.

    Article  PubMed  Google Scholar 

  32. Andersson O, Lindquist B, Lindgren M, Stjernqvist K, Domellöf M, Hellström-Westas L. Effect of delayed cord clamping on neurodevelopment at 4 years of age: a randomized clinical trial. JAMA Pediatr. 2015;169(7):631–8.

    Article  PubMed  Google Scholar 

  33. Garabedian C, Rakza T, Drumez E, et al. Benefits of delayed cord clamping in red blood cell alloimmunization. Pediatrics. 2016;137(3):e20153236.

    Article  PubMed  Google Scholar 

  34. van Kamp IL, Klumper FJ, Meerman RH, et al. Treatment of fetal anemia due to red-cell alloimmunization with intrauterine transfusions in the Netherlands, 1988-1999. Acta Obstet Gynecol Scand. 2004;83(8):731–7.

    Article  PubMed  Google Scholar 

  35. McGlone L, Simpson JH, Scott-Lang C, et al. Short-term outcomes following intrauterine transfusion in Scotland. Arch Dis Child Fetal Neonatal Ed. 2011;96(1):F69–70.

    Article  PubMed  Google Scholar 

  36. Lindenburg IT, Smits-Wintjens VE, van Klink JM, et al. LOTUS study group. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. Am J Obstet Gynecol. 2012;206(2):141, e1-8.

    Article  Google Scholar 

  37. van Klink JMM, van Veen SJ, Smits-Wintjens VEHJ, et al. Immunoglobulins in neonates with Rhesus hemolytic disease of the fetus and newborn: long-term outcome in a randomized trial. Fetal Diagn Ther. 2016;39:209–13.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UT Health Science Center San Antonio, San Antonio, TX, USA

    Alejandra Pena Hernandez

Authors
  1. Alejandra Pena Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alejandra Pena Hernandez .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University of Texas Health Science Center, San Antonio, TX, USA

    Deepak M. Kamat

  2. Department of Pediatrics, Division of Hematology-Oncology, The University of Texas Health Science Center, San Antonio, TX, USA

    Melissa Frei-Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pena Hernandez, A. (2021). Neonatal Immune Hemolytic Anemia. In: Kamat, D., Frei-Jones, M. (eds) Benign Hematologic Disorders in Children. Springer, Cham. https://doi.org/10.1007/978-3-030-49980-8_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-49980-8_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-49979-2

  • Online ISBN: 978-3-030-49980-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation